Antiviral Drug Design: Past, Presence, and Future

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Viral infections pose a significant global health burden, causing millions of deaths annually across various organ systems.
• Lower respiratory infections, gastrointestinal viruses, exanthematous diseases, and hepatic infections contribute substantially to global morbidity and mortality.
• Neurologic, cutaneous, and hemorrhagic viral diseases further highlight the extensive clinical impact and public health challenges.

Purpose of the Study:

• To underscore the critical need for developing and applying a diverse range of antiviral agents.
• To emphasize the importance of both direct and indirect virus-targeting strategies in combating viral diseases.
• To highlight the necessity for continued innovation in antiviral therapies to mitigate the global impact of viral infections.

Main Methods:

• Review of global health data on viral disease burden and mortality.
• Analysis of current antiviral agent mechanisms of action, including direct and indirect targeting.
• Synthesis of information on various viral disease categories and their public health implications.

Main Results:

• Viral diseases cause millions of deaths, with significant impact on respiratory, gastrointestinal, hepatic, and neurologic systems.
• Antiviral agents include direct inhibitors (e.g., protease, polymerase inhibitors) and indirect agents disrupting host pathways.
• A broad spectrum of viral diseases necessitates a comprehensive approach to antiviral development.

Conclusions:

• Continued innovation and comprehensive development of antiviral therapies are essential.
• Diverse antiviral strategies, targeting viruses directly or indirectly, are vital for mitigating the global burden of viral diseases.
• Addressing the multifaceted threat of viral infections requires sustained research and development in antiviral agents.